PCCTC Investigator Andrew J. Armstrong, MD, MS Selected for Rapid Oral Abstract Session at 2026 ASCO Annual Meeting

The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that esteemed PCCTC investigator Andrew J. Armstrong, MD, MS, of Duke University Medical Center and Duke Cancer Institute, has been selected to present his research during the Rapid Oral Abstract Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Armstrong's abstract, Phase 2 Multicenter Trial of Chemoimmunotherapy for Patients with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP), reports results from a multicenter, phase 2 trial evaluating a novel combination of cabazitaxel, carboplatin, ipilimumab, and nivolumab in patients with metastatic neuroendocrine or aggressive variant prostate cancer (NEPC/AVPC), a particularly difficult-to-treat patient population with significant unmet need.

"We are incredibly proud of Dr. Armstrong and the entire CHAMP study team for this well-deserved recognition," said PCCTC CEO, Jake Vinson. "This research represents exactly the kind of innovative, collaborative science the PCCTC was built to advance, and we are excited for the broader oncology community to hear these important findings."

The CHAMP trial, conducted across three centers within the PCCTC, enrolled 40 patients and met its primary endpoint, demonstrating a 6-month radiographic progression-free survival rate of 78%, meaningfully exceeding historical benchmarks for platinum-based chemotherapy alone. The results suggest that dual checkpoint blockade combined with platinum doublet chemotherapy may offer a promising new treatment approach for patients with NEPC/AVPC.

The study (NCT04709276) was funded by Bristol-Myers-Squibb and conducted through the PCCTC. For more information, please contact the PCCTC at pcctc@mskcc.org.

Source: Armstrong AJ, et al. J Clin Oncol 44, 2026 (suppl 16; abstr 5016)